nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—FKBP1A—esophageal cancer	0.74	0.931	CbGaD
Temsirolimus—ABCB1—esophageal cancer	0.0545	0.0686	CbGaD
Temsirolimus—Pimecrolimus—FKBP1A—esophageal cancer	0.00256	0.305	CrCbGaD
Temsirolimus—Everolimus—FKBP1A—esophageal cancer	0.00256	0.305	CrCbGaD
Temsirolimus—MTOR—neck—esophageal cancer	0.00155	0.109	CbGeAlD
Temsirolimus—Tacrolimus—FKBP1A—esophageal cancer	0.00152	0.181	CrCbGaD
Temsirolimus—Sirolimus—FKBP1A—esophageal cancer	0.00152	0.181	CrCbGaD
Temsirolimus—FKBP1A—neck—esophageal cancer	0.00139	0.0983	CbGeAlD
Temsirolimus—MTOR—epithelium—esophageal cancer	0.00105	0.0744	CbGeAlD
Temsirolimus—MTOR—smooth muscle tissue—esophageal cancer	0.00101	0.0717	CbGeAlD
Temsirolimus—FKBP1A—epithelium—esophageal cancer	0.000947	0.0669	CbGeAlD
Temsirolimus—FKBP1A—bronchus—esophageal cancer	0.000933	0.0659	CbGeAlD
Temsirolimus—FKBP1A—smooth muscle tissue—esophageal cancer	0.000913	0.0645	CbGeAlD
Temsirolimus—FKBP1A—trachea—esophageal cancer	0.000838	0.0592	CbGeAlD
Temsirolimus—MTOR—digestive system—esophageal cancer	0.000801	0.0566	CbGeAlD
Temsirolimus—FKBP1A—digestive system—esophageal cancer	0.000721	0.0509	CbGeAlD
Temsirolimus—MTOR—lung—esophageal cancer	0.000669	0.0473	CbGeAlD
Temsirolimus—Extravasation—Cisplatin—esophageal cancer	0.00063	0.00655	CcSEcCtD
Temsirolimus—Nail disorder—Capecitabine—esophageal cancer	0.000624	0.00649	CcSEcCtD
Temsirolimus—Interstitial pneumonia—Methotrexate—esophageal cancer	0.000624	0.00649	CcSEcCtD
Temsirolimus—Blood triglycerides increased—Capecitabine—esophageal cancer	0.000618	0.00643	CcSEcCtD
Temsirolimus—Cellulitis—Cisplatin—esophageal cancer	0.000604	0.00628	CcSEcCtD
Temsirolimus—FKBP1A—lung—esophageal cancer	0.000602	0.0425	CbGeAlD
Temsirolimus—Haemoglobin decreased—Capecitabine—esophageal cancer	0.000588	0.00612	CcSEcCtD
Temsirolimus—Pain—Carboplatin—esophageal cancer	0.000571	0.00594	CcSEcCtD
Temsirolimus—Laryngitis—Capecitabine—esophageal cancer	0.000562	0.00584	CcSEcCtD
Temsirolimus—Mucosal inflammation—Methotrexate—esophageal cancer	0.000544	0.00566	CcSEcCtD
Temsirolimus—Herpes zoster—Capecitabine—esophageal cancer	0.000538	0.00559	CcSEcCtD
Temsirolimus—Pleural effusion—Capecitabine—esophageal cancer	0.000529	0.0055	CcSEcCtD
Temsirolimus—Body temperature increased—Carboplatin—esophageal cancer	0.000528	0.00549	CcSEcCtD
Temsirolimus—Fungal infection—Capecitabine—esophageal cancer	0.000524	0.00545	CcSEcCtD
Temsirolimus—Fluid retention—Cisplatin—esophageal cancer	0.000521	0.00542	CcSEcCtD
Temsirolimus—Febrile neutropenia—Methotrexate—esophageal cancer	0.000501	0.00521	CcSEcCtD
Temsirolimus—Ageusia—Capecitabine—esophageal cancer	0.0005	0.0052	CcSEcCtD
Temsirolimus—Deep vein thrombosis—Methotrexate—esophageal cancer	0.000495	0.00515	CcSEcCtD
Temsirolimus—Petechiae—Capecitabine—esophageal cancer	0.000492	0.00512	CcSEcCtD
Temsirolimus—Folliculitis—Methotrexate—esophageal cancer	0.00048	0.00499	CcSEcCtD
Temsirolimus—Nail disorder—Methotrexate—esophageal cancer	0.000465	0.00483	CcSEcCtD
Temsirolimus—MTOR—lymph node—esophageal cancer	0.000458	0.0323	CbGeAlD
Temsirolimus—Rectal haemorrhage—Capecitabine—esophageal cancer	0.000448	0.00466	CcSEcCtD
Temsirolimus—Cellulitis—Capecitabine—esophageal cancer	0.000445	0.00463	CcSEcCtD
Temsirolimus—Hypocalcaemia—Capecitabine—esophageal cancer	0.000442	0.0046	CcSEcCtD
Temsirolimus—Herpes simplex—Capecitabine—esophageal cancer	0.000439	0.00457	CcSEcCtD
Temsirolimus—Blood bilirubin increased—Capecitabine—esophageal cancer	0.000428	0.00445	CcSEcCtD
Temsirolimus—Lung disorder—Methotrexate—esophageal cancer	0.000426	0.00443	CcSEcCtD
Temsirolimus—Interstitial lung disease—Methotrexate—esophageal cancer	0.000426	0.00443	CcSEcCtD
Temsirolimus—Cataract—Capecitabine—esophageal cancer	0.000425	0.00442	CcSEcCtD
Temsirolimus—FKBP1A—lymph node—esophageal cancer	0.000412	0.0291	CbGeAlD
Temsirolimus—Pulmonary embolism—Capecitabine—esophageal cancer	0.000405	0.00421	CcSEcCtD
Temsirolimus—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.000405	0.00421	CcSEcCtD
Temsirolimus—Herpes zoster—Methotrexate—esophageal cancer	0.0004	0.00416	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.000399	0.00415	CcSEcCtD
Temsirolimus—Pleural effusion—Methotrexate—esophageal cancer	0.000394	0.00409	CcSEcCtD
Temsirolimus—Fungal infection—Methotrexate—esophageal cancer	0.00039	0.00406	CcSEcCtD
Temsirolimus—Candida infection—Capecitabine—esophageal cancer	0.000387	0.00402	CcSEcCtD
Temsirolimus—Face oedema—Cisplatin—esophageal cancer	0.000385	0.004	CcSEcCtD
Temsirolimus—Fluid retention—Capecitabine—esophageal cancer	0.000384	0.004	CcSEcCtD
Temsirolimus—Gingivitis—Methotrexate—esophageal cancer	0.000384	0.00399	CcSEcCtD
Temsirolimus—Abscess—Methotrexate—esophageal cancer	0.000381	0.00396	CcSEcCtD
Temsirolimus—Blood creatinine increased—Cisplatin—esophageal cancer	0.000374	0.00388	CcSEcCtD
Temsirolimus—Dehydration—Cisplatin—esophageal cancer	0.000371	0.00386	CcSEcCtD
Temsirolimus—Petechiae—Methotrexate—esophageal cancer	0.000366	0.00381	CcSEcCtD
Temsirolimus—Mouth ulceration—Capecitabine—esophageal cancer	0.000366	0.00381	CcSEcCtD
Temsirolimus—Ecchymosis—Capecitabine—esophageal cancer	0.000366	0.00381	CcSEcCtD
Temsirolimus—Hypokalaemia—Cisplatin—esophageal cancer	0.000363	0.00377	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000359	0.00373	CcSEcCtD
Temsirolimus—Sepsis—Capecitabine—esophageal cancer	0.000351	0.00365	CcSEcCtD
Temsirolimus—Extravasation—Methotrexate—esophageal cancer	0.000345	0.00359	CcSEcCtD
Temsirolimus—Thrombophlebitis—Capecitabine—esophageal cancer	0.00034	0.00353	CcSEcCtD
Temsirolimus—Diabetes mellitus—Capecitabine—esophageal cancer	0.000338	0.00351	CcSEcCtD
Temsirolimus—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.000338	0.00351	CcSEcCtD
Temsirolimus—Swelling—Capecitabine—esophageal cancer	0.000333	0.00346	CcSEcCtD
Temsirolimus—Herpes simplex—Methotrexate—esophageal cancer	0.000327	0.0034	CcSEcCtD
Temsirolimus—Glossitis—Methotrexate—esophageal cancer	0.000327	0.0034	CcSEcCtD
Temsirolimus—CYP3A5—digestive system—esophageal cancer	0.000314	0.0222	CbGeAlD
Temsirolimus—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000311	0.00324	CcSEcCtD
Temsirolimus—Dermatitis bullous—Capecitabine—esophageal cancer	0.000308	0.0032	CcSEcCtD
Temsirolimus—Renal failure—Cisplatin—esophageal cancer	0.000302	0.00314	CcSEcCtD
Temsirolimus—Pulmonary embolism—Methotrexate—esophageal cancer	0.000301	0.00313	CcSEcCtD
Temsirolimus—Stomatitis—Cisplatin—esophageal cancer	0.0003	0.00311	CcSEcCtD
Temsirolimus—Conjunctivitis—Cisplatin—esophageal cancer	0.000299	0.00311	CcSEcCtD
Temsirolimus—Cystitis noninfective—Methotrexate—esophageal cancer	0.000294	0.00306	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000294	0.00306	CcSEcCtD
Temsirolimus—Cystitis—Methotrexate—esophageal cancer	0.000291	0.00303	CcSEcCtD
Temsirolimus—Face oedema—Capecitabine—esophageal cancer	0.000284	0.00295	CcSEcCtD
Temsirolimus—Blood creatinine increased—Capecitabine—esophageal cancer	0.000275	0.00286	CcSEcCtD
Temsirolimus—Dehydration—Capecitabine—esophageal cancer	0.000273	0.00284	CcSEcCtD
Temsirolimus—Ecchymosis—Methotrexate—esophageal cancer	0.000273	0.00283	CcSEcCtD
Temsirolimus—Bladder pain—Methotrexate—esophageal cancer	0.000273	0.00283	CcSEcCtD
Temsirolimus—Mouth ulceration—Methotrexate—esophageal cancer	0.000273	0.00283	CcSEcCtD
Temsirolimus—Urinary tract disorder—Cisplatin—esophageal cancer	0.000272	0.00283	CcSEcCtD
Temsirolimus—Connective tissue disorder—Cisplatin—esophageal cancer	0.000271	0.00282	CcSEcCtD
Temsirolimus—Urethral disorder—Cisplatin—esophageal cancer	0.00027	0.00281	CcSEcCtD
Temsirolimus—Dry skin—Capecitabine—esophageal cancer	0.000269	0.0028	CcSEcCtD
Temsirolimus—Hypokalaemia—Capecitabine—esophageal cancer	0.000267	0.00278	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000265	0.00275	CcSEcCtD
Temsirolimus—CYP3A5—lung—esophageal cancer	0.000262	0.0185	CbGeAlD
Temsirolimus—Sepsis—Methotrexate—esophageal cancer	0.000262	0.00272	CcSEcCtD
Temsirolimus—Gastritis—Capecitabine—esophageal cancer	0.00026	0.00271	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000259	0.0027	CcSEcCtD
Temsirolimus—Eye disorder—Cisplatin—esophageal cancer	0.000258	0.00268	CcSEcCtD
Temsirolimus—Cardiac disorder—Cisplatin—esophageal cancer	0.000256	0.00266	CcSEcCtD
Temsirolimus—Abdominal distension—Capecitabine—esophageal cancer	0.000256	0.00266	CcSEcCtD
Temsirolimus—Dysphagia—Capecitabine—esophageal cancer	0.000254	0.00264	CcSEcCtD
Temsirolimus—Influenza—Capecitabine—esophageal cancer	0.000254	0.00264	CcSEcCtD
Temsirolimus—Thrombophlebitis—Methotrexate—esophageal cancer	0.000253	0.00263	CcSEcCtD
Temsirolimus—Diabetes mellitus—Methotrexate—esophageal cancer	0.000252	0.00262	CcSEcCtD
Temsirolimus—Immune system disorder—Cisplatin—esophageal cancer	0.000249	0.00259	CcSEcCtD
Temsirolimus—Mediastinal disorder—Cisplatin—esophageal cancer	0.000249	0.00259	CcSEcCtD
Temsirolimus—Bronchitis—Capecitabine—esophageal cancer	0.000244	0.00254	CcSEcCtD
Temsirolimus—Erythema—Cisplatin—esophageal cancer	0.00024	0.0025	CcSEcCtD
Temsirolimus—Malnutrition—Cisplatin—esophageal cancer	0.00024	0.0025	CcSEcCtD
Temsirolimus—Dysuria—Capecitabine—esophageal cancer	0.000238	0.00247	CcSEcCtD
Temsirolimus—Neutropenia—Capecitabine—esophageal cancer	0.000238	0.00247	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000236	0.00246	CcSEcCtD
Temsirolimus—CYP3A4—digestive system—esophageal cancer	0.000235	0.0166	CbGeAlD
Temsirolimus—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000232	0.00241	CcSEcCtD
Temsirolimus—CYP2D6—digestive system—esophageal cancer	0.000232	0.0164	CbGeAlD
Temsirolimus—Weight decreased—Capecitabine—esophageal cancer	0.00023	0.00239	CcSEcCtD
Temsirolimus—Hyperglycaemia—Capecitabine—esophageal cancer	0.000229	0.00238	CcSEcCtD
Temsirolimus—Pneumonia—Capecitabine—esophageal cancer	0.000228	0.00237	CcSEcCtD
Temsirolimus—Infestation NOS—Capecitabine—esophageal cancer	0.000227	0.00236	CcSEcCtD
Temsirolimus—Infestation—Capecitabine—esophageal cancer	0.000227	0.00236	CcSEcCtD
Temsirolimus—Depression—Capecitabine—esophageal cancer	0.000226	0.00235	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000225	0.00234	CcSEcCtD
Temsirolimus—Renal failure—Capecitabine—esophageal cancer	0.000223	0.00232	CcSEcCtD
Temsirolimus—Anaemia—Cisplatin—esophageal cancer	0.000222	0.00231	CcSEcCtD
Temsirolimus—Stomatitis—Capecitabine—esophageal cancer	0.000221	0.0023	CcSEcCtD
Temsirolimus—Urinary tract infection—Capecitabine—esophageal cancer	0.00022	0.00229	CcSEcCtD
Temsirolimus—Conjunctivitis—Capecitabine—esophageal cancer	0.00022	0.00229	CcSEcCtD
Temsirolimus—ABCB1—epithelium—esophageal cancer	0.000219	0.0155	CbGeAlD
Temsirolimus—Haematuria—Capecitabine—esophageal cancer	0.000216	0.00225	CcSEcCtD
Temsirolimus—Leukopenia—Cisplatin—esophageal cancer	0.000215	0.00224	CcSEcCtD
Temsirolimus—Epistaxis—Capecitabine—esophageal cancer	0.000214	0.00222	CcSEcCtD
Temsirolimus—Convulsion—Cisplatin—esophageal cancer	0.000208	0.00216	CcSEcCtD
Temsirolimus—Myalgia—Cisplatin—esophageal cancer	0.000204	0.00213	CcSEcCtD
Temsirolimus—Rhinitis—Capecitabine—esophageal cancer	0.000204	0.00212	CcSEcCtD
Temsirolimus—Anxiety—Cisplatin—esophageal cancer	0.000204	0.00212	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000203	0.00211	CcSEcCtD
Temsirolimus—Pharyngitis—Capecitabine—esophageal cancer	0.000202	0.0021	CcSEcCtD
Temsirolimus—Urinary tract disorder—Capecitabine—esophageal cancer	0.000201	0.00209	CcSEcCtD
Temsirolimus—Oedema peripheral—Capecitabine—esophageal cancer	0.0002	0.00208	CcSEcCtD
Temsirolimus—Connective tissue disorder—Capecitabine—esophageal cancer	0.0002	0.00208	CcSEcCtD
Temsirolimus—Urethral disorder—Capecitabine—esophageal cancer	0.000199	0.00207	CcSEcCtD
Temsirolimus—Anaphylactic shock—Cisplatin—esophageal cancer	0.000196	0.00204	CcSEcCtD
Temsirolimus—Oedema—Cisplatin—esophageal cancer	0.000196	0.00204	CcSEcCtD
Temsirolimus—Infection—Cisplatin—esophageal cancer	0.000195	0.00202	CcSEcCtD
Temsirolimus—ABCB1—trachea—esophageal cancer	0.000194	0.0137	CbGeAlD
Temsirolimus—Erythema multiforme—Capecitabine—esophageal cancer	0.000192	0.002	CcSEcCtD
Temsirolimus—Nervous system disorder—Cisplatin—esophageal cancer	0.000192	0.002	CcSEcCtD
Temsirolimus—Thrombocytopenia—Cisplatin—esophageal cancer	0.000192	0.002	CcSEcCtD
Temsirolimus—Skin disorder—Cisplatin—esophageal cancer	0.00019	0.00198	CcSEcCtD
Temsirolimus—Eye disorder—Capecitabine—esophageal cancer	0.00019	0.00198	CcSEcCtD
Temsirolimus—Cardiac disorder—Capecitabine—esophageal cancer	0.000189	0.00196	CcSEcCtD
Temsirolimus—Anorexia—Cisplatin—esophageal cancer	0.000187	0.00194	CcSEcCtD
Temsirolimus—Angiopathy—Capecitabine—esophageal cancer	0.000184	0.00192	CcSEcCtD
Temsirolimus—Immune system disorder—Capecitabine—esophageal cancer	0.000184	0.00191	CcSEcCtD
Temsirolimus—Mediastinal disorder—Capecitabine—esophageal cancer	0.000183	0.00191	CcSEcCtD
Temsirolimus—Chills—Capecitabine—esophageal cancer	0.000182	0.0019	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000179	0.00186	CcSEcCtD
Temsirolimus—Mental disorder—Capecitabine—esophageal cancer	0.000178	0.00185	CcSEcCtD
Temsirolimus—Malnutrition—Capecitabine—esophageal cancer	0.000177	0.00184	CcSEcCtD
Temsirolimus—Erythema—Capecitabine—esophageal cancer	0.000177	0.00184	CcSEcCtD
Temsirolimus—Dysuria—Methotrexate—esophageal cancer	0.000177	0.00184	CcSEcCtD
Temsirolimus—Neutropenia—Methotrexate—esophageal cancer	0.000177	0.00184	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000176	0.00183	CcSEcCtD
Temsirolimus—Dyspnoea—Cisplatin—esophageal cancer	0.000175	0.00182	CcSEcCtD
Temsirolimus—Dysgeusia—Capecitabine—esophageal cancer	0.000173	0.0018	CcSEcCtD
Temsirolimus—Back pain—Capecitabine—esophageal cancer	0.000171	0.00178	CcSEcCtD
Temsirolimus—Decreased appetite—Cisplatin—esophageal cancer	0.00017	0.00177	CcSEcCtD
Temsirolimus—Pneumonia—Methotrexate—esophageal cancer	0.00017	0.00176	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000169	0.00176	CcSEcCtD
Temsirolimus—Infestation—Methotrexate—esophageal cancer	0.000169	0.00175	CcSEcCtD
Temsirolimus—Infestation NOS—Methotrexate—esophageal cancer	0.000169	0.00175	CcSEcCtD
Temsirolimus—Depression—Methotrexate—esophageal cancer	0.000168	0.00175	CcSEcCtD
Temsirolimus—Pain—Cisplatin—esophageal cancer	0.000168	0.00174	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000167	0.00174	CcSEcCtD
Temsirolimus—ABCB1—digestive system—esophageal cancer	0.000167	0.0118	CbGeAlD
Temsirolimus—Renal failure—Methotrexate—esophageal cancer	0.000166	0.00172	CcSEcCtD
Temsirolimus—Stomatitis—Methotrexate—esophageal cancer	0.000164	0.00171	CcSEcCtD
Temsirolimus—Conjunctivitis—Methotrexate—esophageal cancer	0.000164	0.0017	CcSEcCtD
Temsirolimus—Anaemia—Capecitabine—esophageal cancer	0.000164	0.0017	CcSEcCtD
Temsirolimus—Haematuria—Methotrexate—esophageal cancer	0.000161	0.00167	CcSEcCtD
Temsirolimus—Epistaxis—Methotrexate—esophageal cancer	0.000159	0.00165	CcSEcCtD
Temsirolimus—Leukopenia—Capecitabine—esophageal cancer	0.000158	0.00165	CcSEcCtD
Temsirolimus—Body temperature increased—Cisplatin—esophageal cancer	0.000155	0.00161	CcSEcCtD
Temsirolimus—Cough—Capecitabine—esophageal cancer	0.000154	0.00161	CcSEcCtD
Temsirolimus—Hypertension—Capecitabine—esophageal cancer	0.000153	0.00159	CcSEcCtD
Temsirolimus—Arthralgia—Capecitabine—esophageal cancer	0.000151	0.00157	CcSEcCtD
Temsirolimus—Myalgia—Capecitabine—esophageal cancer	0.000151	0.00157	CcSEcCtD
Temsirolimus—Chest pain—Capecitabine—esophageal cancer	0.000151	0.00157	CcSEcCtD
Temsirolimus—Pharyngitis—Methotrexate—esophageal cancer	0.00015	0.00156	CcSEcCtD
Temsirolimus—Anxiety—Capecitabine—esophageal cancer	0.00015	0.00156	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00015	0.00156	CcSEcCtD
Temsirolimus—Urinary tract disorder—Methotrexate—esophageal cancer	0.000149	0.00155	CcSEcCtD
Temsirolimus—Urethral disorder—Methotrexate—esophageal cancer	0.000148	0.00154	CcSEcCtD
Temsirolimus—Oedema—Capecitabine—esophageal cancer	0.000144	0.0015	CcSEcCtD
Temsirolimus—Hypersensitivity—Cisplatin—esophageal cancer	0.000144	0.0015	CcSEcCtD
Temsirolimus—Infection—Capecitabine—esophageal cancer	0.000144	0.00149	CcSEcCtD
Temsirolimus—Erythema multiforme—Methotrexate—esophageal cancer	0.000143	0.00149	CcSEcCtD
Temsirolimus—Nervous system disorder—Capecitabine—esophageal cancer	0.000142	0.00147	CcSEcCtD
Temsirolimus—Eye disorder—Methotrexate—esophageal cancer	0.000141	0.00147	CcSEcCtD
Temsirolimus—Thrombocytopenia—Capecitabine—esophageal cancer	0.000141	0.00147	CcSEcCtD
Temsirolimus—Asthenia—Cisplatin—esophageal cancer	0.000141	0.00146	CcSEcCtD
Temsirolimus—Cardiac disorder—Methotrexate—esophageal cancer	0.00014	0.00146	CcSEcCtD
Temsirolimus—Skin disorder—Capecitabine—esophageal cancer	0.00014	0.00146	CcSEcCtD
Temsirolimus—ABCB1—lung—esophageal cancer	0.000139	0.00984	CbGeAlD
Temsirolimus—Anorexia—Capecitabine—esophageal cancer	0.000138	0.00143	CcSEcCtD
Temsirolimus—Angiopathy—Methotrexate—esophageal cancer	0.000137	0.00143	CcSEcCtD
Temsirolimus—Immune system disorder—Methotrexate—esophageal cancer	0.000137	0.00142	CcSEcCtD
Temsirolimus—Mediastinal disorder—Methotrexate—esophageal cancer	0.000136	0.00142	CcSEcCtD
Temsirolimus—Chills—Methotrexate—esophageal cancer	0.000136	0.00141	CcSEcCtD
Temsirolimus—Diarrhoea—Cisplatin—esophageal cancer	0.000134	0.00139	CcSEcCtD
Temsirolimus—Mental disorder—Methotrexate—esophageal cancer	0.000133	0.00138	CcSEcCtD
Temsirolimus—Erythema—Methotrexate—esophageal cancer	0.000132	0.00137	CcSEcCtD
Temsirolimus—Malnutrition—Methotrexate—esophageal cancer	0.000132	0.00137	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000132	0.00137	CcSEcCtD
Temsirolimus—Insomnia—Capecitabine—esophageal cancer	0.000131	0.00136	CcSEcCtD
Temsirolimus—Dysgeusia—Methotrexate—esophageal cancer	0.000129	0.00134	CcSEcCtD
Temsirolimus—Dyspnoea—Capecitabine—esophageal cancer	0.000129	0.00134	CcSEcCtD
Temsirolimus—Back pain—Methotrexate—esophageal cancer	0.000127	0.00133	CcSEcCtD
Temsirolimus—Decreased appetite—Capecitabine—esophageal cancer	0.000126	0.00131	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000125	0.0013	CcSEcCtD
Temsirolimus—Vomiting—Cisplatin—esophageal cancer	0.000125	0.0013	CcSEcCtD
Temsirolimus—Fatigue—Capecitabine—esophageal cancer	0.000125	0.0013	CcSEcCtD
Temsirolimus—Rash—Cisplatin—esophageal cancer	0.000124	0.00129	CcSEcCtD
Temsirolimus—Pain—Capecitabine—esophageal cancer	0.000124	0.00128	CcSEcCtD
Temsirolimus—Constipation—Capecitabine—esophageal cancer	0.000124	0.00128	CcSEcCtD
Temsirolimus—Dermatitis—Cisplatin—esophageal cancer	0.000123	0.00128	CcSEcCtD
Temsirolimus—Anaemia—Methotrexate—esophageal cancer	0.000122	0.00127	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000118	0.00123	CcSEcCtD
Temsirolimus—Leukopenia—Methotrexate—esophageal cancer	0.000118	0.00123	CcSEcCtD
Temsirolimus—Nausea—Cisplatin—esophageal cancer	0.000116	0.00121	CcSEcCtD
Temsirolimus—Cough—Methotrexate—esophageal cancer	0.000115	0.0012	CcSEcCtD
Temsirolimus—Abdominal pain—Capecitabine—esophageal cancer	0.000114	0.00119	CcSEcCtD
Temsirolimus—Body temperature increased—Capecitabine—esophageal cancer	0.000114	0.00119	CcSEcCtD
Temsirolimus—Convulsion—Methotrexate—esophageal cancer	0.000114	0.00119	CcSEcCtD
Temsirolimus—Myalgia—Methotrexate—esophageal cancer	0.000112	0.00117	CcSEcCtD
Temsirolimus—Arthralgia—Methotrexate—esophageal cancer	0.000112	0.00117	CcSEcCtD
Temsirolimus—Chest pain—Methotrexate—esophageal cancer	0.000112	0.00117	CcSEcCtD
Temsirolimus—Sirolimus—ABCB1—esophageal cancer	0.000112	0.0134	CrCbGaD
Temsirolimus—Tacrolimus—ABCB1—esophageal cancer	0.000112	0.0134	CrCbGaD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000111	0.00116	CcSEcCtD
Temsirolimus—Anaphylactic shock—Methotrexate—esophageal cancer	0.000108	0.00112	CcSEcCtD
Temsirolimus—Infection—Methotrexate—esophageal cancer	0.000107	0.00111	CcSEcCtD
Temsirolimus—Hypersensitivity—Capecitabine—esophageal cancer	0.000106	0.00111	CcSEcCtD
Temsirolimus—Nervous system disorder—Methotrexate—esophageal cancer	0.000105	0.0011	CcSEcCtD
Temsirolimus—Thrombocytopenia—Methotrexate—esophageal cancer	0.000105	0.0011	CcSEcCtD
Temsirolimus—Skin disorder—Methotrexate—esophageal cancer	0.000104	0.00109	CcSEcCtD
Temsirolimus—Asthenia—Capecitabine—esophageal cancer	0.000104	0.00108	CcSEcCtD
Temsirolimus—Anorexia—Methotrexate—esophageal cancer	0.000103	0.00107	CcSEcCtD
Temsirolimus—Pruritus—Capecitabine—esophageal cancer	0.000102	0.00106	CcSEcCtD
Temsirolimus—Diarrhoea—Capecitabine—esophageal cancer	9.88e-05	0.00103	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Methotrexate—esophageal cancer	9.8e-05	0.00102	CcSEcCtD
Temsirolimus—Insomnia—Methotrexate—esophageal cancer	9.73e-05	0.00101	CcSEcCtD
Temsirolimus—Dyspnoea—Methotrexate—esophageal cancer	9.59e-05	0.000997	CcSEcCtD
Temsirolimus—Somnolence—Methotrexate—esophageal cancer	9.56e-05	0.000994	CcSEcCtD
Temsirolimus—Dizziness—Capecitabine—esophageal cancer	9.55e-05	0.000993	CcSEcCtD
Temsirolimus—ABCB1—lymph node—esophageal cancer	9.52e-05	0.00673	CbGeAlD
Temsirolimus—Decreased appetite—Methotrexate—esophageal cancer	9.35e-05	0.000972	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Methotrexate—esophageal cancer	9.28e-05	0.000966	CcSEcCtD
Temsirolimus—Fatigue—Methotrexate—esophageal cancer	9.27e-05	0.000964	CcSEcCtD
Temsirolimus—Pain—Methotrexate—esophageal cancer	9.2e-05	0.000956	CcSEcCtD
Temsirolimus—Vomiting—Capecitabine—esophageal cancer	9.18e-05	0.000955	CcSEcCtD
Temsirolimus—Rash—Capecitabine—esophageal cancer	9.11e-05	0.000947	CcSEcCtD
Temsirolimus—Dermatitis—Capecitabine—esophageal cancer	9.1e-05	0.000946	CcSEcCtD
Temsirolimus—Headache—Capecitabine—esophageal cancer	9.05e-05	0.000941	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Methotrexate—esophageal cancer	8.79e-05	0.000915	CcSEcCtD
Temsirolimus—Nausea—Capecitabine—esophageal cancer	8.58e-05	0.000892	CcSEcCtD
Temsirolimus—Abdominal pain—Methotrexate—esophageal cancer	8.5e-05	0.000884	CcSEcCtD
Temsirolimus—Body temperature increased—Methotrexate—esophageal cancer	8.5e-05	0.000884	CcSEcCtD
Temsirolimus—Hypersensitivity—Methotrexate—esophageal cancer	7.92e-05	0.000824	CcSEcCtD
Temsirolimus—Asthenia—Methotrexate—esophageal cancer	7.72e-05	0.000802	CcSEcCtD
Temsirolimus—Pruritus—Methotrexate—esophageal cancer	7.61e-05	0.000791	CcSEcCtD
Temsirolimus—Diarrhoea—Methotrexate—esophageal cancer	7.36e-05	0.000765	CcSEcCtD
Temsirolimus—Dizziness—Methotrexate—esophageal cancer	7.11e-05	0.00074	CcSEcCtD
Temsirolimus—Vomiting—Methotrexate—esophageal cancer	6.84e-05	0.000711	CcSEcCtD
Temsirolimus—Rash—Methotrexate—esophageal cancer	6.78e-05	0.000705	CcSEcCtD
Temsirolimus—Dermatitis—Methotrexate—esophageal cancer	6.77e-05	0.000704	CcSEcCtD
Temsirolimus—Headache—Methotrexate—esophageal cancer	6.74e-05	0.000701	CcSEcCtD
Temsirolimus—Nausea—Methotrexate—esophageal cancer	6.39e-05	0.000664	CcSEcCtD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	2.27e-05	0.000263	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—BLVRB—esophageal cancer	2.27e-05	0.000262	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SLC52A3—esophageal cancer	2.27e-05	0.000262	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HIST1H2BM—esophageal cancer	2.23e-05	0.000257	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—EGFR—esophageal cancer	2.22e-05	0.000256	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PDE4D—esophageal cancer	2.21e-05	0.000255	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CASP8—esophageal cancer	2.19e-05	0.000253	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ALDOB—esophageal cancer	2.18e-05	0.000252	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SMAD4—esophageal cancer	2.18e-05	0.000252	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CREBBP—esophageal cancer	2.18e-05	0.000252	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PLCE1—esophageal cancer	2.17e-05	0.000251	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ADH7—esophageal cancer	2.17e-05	0.000251	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—BLVRB—esophageal cancer	2.14e-05	0.000247	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SLC52A3—esophageal cancer	2.14e-05	0.000247	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GAPDH—esophageal cancer	2.1e-05	0.000243	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—GNG7—esophageal cancer	2.1e-05	0.000243	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CREBBP—esophageal cancer	2.08e-05	0.000241	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CRABP1—esophageal cancer	2.08e-05	0.000241	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—esophageal cancer	1.98e-05	0.000229	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GNG7—esophageal cancer	1.98e-05	0.000229	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—XIAP—esophageal cancer	1.97e-05	0.000227	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ABL1—esophageal cancer	1.96e-05	0.000227	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	1.96e-05	0.000226	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CA1—esophageal cancer	1.93e-05	0.000223	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SLC10A2—esophageal cancer	1.93e-05	0.000223	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—PIK3CA—esophageal cancer	1.92e-05	0.000222	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ADH1B—esophageal cancer	1.9e-05	0.00022	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	1.9e-05	0.00022	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—BCL2—esophageal cancer	1.88e-05	0.000217	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NOS3—esophageal cancer	1.86e-05	0.000216	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CTNNA1—esophageal cancer	1.86e-05	0.000215	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	1.86e-05	0.000215	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ALDH2—esophageal cancer	1.86e-05	0.000215	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TGFBR2—esophageal cancer	1.85e-05	0.000214	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CXCL2—esophageal cancer	1.85e-05	0.000214	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—ERBB2—esophageal cancer	1.82e-05	0.000211	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—TYMP—esophageal cancer	1.82e-05	0.00021	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SLC10A2—esophageal cancer	1.82e-05	0.00021	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CA1—esophageal cancer	1.82e-05	0.00021	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HIF1A—esophageal cancer	1.79e-05	0.000206	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP26A1—esophageal cancer	1.77e-05	0.000205	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GSTT1—esophageal cancer	1.77e-05	0.000204	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CA2—esophageal cancer	1.76e-05	0.000204	CbGpPWpGaD
Temsirolimus—MTOR—Disease—SMAD4—esophageal cancer	1.75e-05	0.000203	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—ERBB2—esophageal cancer	1.75e-05	0.000202	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CYP2A6—esophageal cancer	1.75e-05	0.000202	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—ERBB2—esophageal cancer	1.74e-05	0.000202	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PSME2—esophageal cancer	1.73e-05	0.0002	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PSME1—esophageal cancer	1.73e-05	0.0002	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ALOX15—esophageal cancer	1.73e-05	0.000199	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ANXA1—esophageal cancer	1.72e-05	0.000199	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KDR—esophageal cancer	1.71e-05	0.000197	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTGS2—esophageal cancer	1.71e-05	0.000197	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.68e-05	0.000194	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SST—esophageal cancer	1.67e-05	0.000193	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CA2—esophageal cancer	1.66e-05	0.000192	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ENO1—esophageal cancer	1.65e-05	0.000191	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS1—esophageal cancer	1.65e-05	0.000191	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—TPI1—esophageal cancer	1.65e-05	0.00019	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTO1—esophageal cancer	1.65e-05	0.00019	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PLCE1—esophageal cancer	1.64e-05	0.000189	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ADH7—esophageal cancer	1.64e-05	0.000189	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PSME2—esophageal cancer	1.63e-05	0.000188	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PSME1—esophageal cancer	1.63e-05	0.000188	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NOTCH3—esophageal cancer	1.63e-05	0.000188	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—GHRL—esophageal cancer	1.63e-05	0.000188	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.63e-05	0.000188	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NOTCH1—esophageal cancer	1.61e-05	0.000186	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FBXW7—esophageal cancer	1.6e-05	0.000185	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ALDOB—esophageal cancer	1.58e-05	0.000182	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CDKN1A—esophageal cancer	1.56e-05	0.00018	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.55e-05	0.000179	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PLCE1—esophageal cancer	1.54e-05	0.000179	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ADH7—esophageal cancer	1.54e-05	0.000179	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GAPDH—esophageal cancer	1.52e-05	0.000176	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CRABP1—esophageal cancer	1.51e-05	0.000174	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CDKN1A—esophageal cancer	1.5e-05	0.000173	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CDKN1A—esophageal cancer	1.49e-05	0.000172	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—TLR4—esophageal cancer	1.49e-05	0.000172	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—EP300—esophageal cancer	1.48e-05	0.000171	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NOTCH2—esophageal cancer	1.46e-05	0.000169	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CREBBP—esophageal cancer	1.46e-05	0.000169	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ADH1B—esophageal cancer	1.44e-05	0.000166	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HIF1A—esophageal cancer	1.43e-05	0.000166	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GNG7—esophageal cancer	1.43e-05	0.000166	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—EP300—esophageal cancer	1.42e-05	0.000164	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CYP1B1—esophageal cancer	1.41e-05	0.000163	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.41e-05	0.000162	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.4e-05	0.000161	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.4e-05	0.000161	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—TYMP—esophageal cancer	1.37e-05	0.000159	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ADH1B—esophageal cancer	1.35e-05	0.000157	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.35e-05	0.000156	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ALDH2—esophageal cancer	1.34e-05	0.000155	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.34e-05	0.000154	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CYP19A1—esophageal cancer	1.32e-05	0.000153	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.32e-05	0.000152	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NOS3—esophageal cancer	1.31e-05	0.000151	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NOS2—esophageal cancer	1.3e-05	0.000151	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ALOX15—esophageal cancer	1.3e-05	0.000151	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TGFBR2—esophageal cancer	1.3e-05	0.00015	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—TYMP—esophageal cancer	1.29e-05	0.00015	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NOTCH1—esophageal cancer	1.29e-05	0.000149	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTT1—esophageal cancer	1.28e-05	0.000148	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CASP8—esophageal cancer	1.27e-05	0.000147	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CREBBP—esophageal cancer	1.27e-05	0.000147	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—EGFR—esophageal cancer	1.26e-05	0.000146	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP2A6—esophageal cancer	1.26e-05	0.000146	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP26A1—esophageal cancer	1.26e-05	0.000146	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—TPI1—esophageal cancer	1.24e-05	0.000144	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTO1—esophageal cancer	1.24e-05	0.000144	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MYC—esophageal cancer	1.24e-05	0.000143	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SMAD4—esophageal cancer	1.23e-05	0.000142	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ALOX15—esophageal cancer	1.23e-05	0.000142	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ERBB2—esophageal cancer	1.22e-05	0.000141	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—EGFR—esophageal cancer	1.21e-05	0.00014	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—EGFR—esophageal cancer	1.21e-05	0.00014	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—HMOX1—esophageal cancer	1.21e-05	0.00014	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS1—esophageal cancer	1.2e-05	0.000138	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ENO1—esophageal cancer	1.2e-05	0.000138	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ALDOB—esophageal cancer	1.19e-05	0.000138	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.19e-05	0.000137	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CA1—esophageal cancer	1.19e-05	0.000137	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PSME2—esophageal cancer	1.18e-05	0.000136	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PSME1—esophageal cancer	1.18e-05	0.000136	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CREBBP—esophageal cancer	1.17e-05	0.000135	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTO1—esophageal cancer	1.17e-05	0.000135	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—TPI1—esophageal cancer	1.17e-05	0.000135	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ABCB1—esophageal cancer	1.16e-05	0.000134	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GAPDH—esophageal cancer	1.15e-05	0.000133	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.14e-05	0.000132	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CRABP1—esophageal cancer	1.14e-05	0.000131	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ALDOB—esophageal cancer	1.12e-05	0.00013	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.11e-05	0.000128	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PIK3CA—esophageal cancer	1.1e-05	0.000127	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—BCL2—esophageal cancer	1.09e-05	0.000126	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CA2—esophageal cancer	1.09e-05	0.000126	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GNG7—esophageal cancer	1.08e-05	0.000125	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GAPDH—esophageal cancer	1.08e-05	0.000125	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CCND1—esophageal cancer	1.08e-05	0.000125	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CRABP1—esophageal cancer	1.07e-05	0.000124	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ERBB2—esophageal cancer	1.06e-05	0.000123	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PIK3CA—esophageal cancer	1.05e-05	0.000122	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PIK3CA—esophageal cancer	1.05e-05	0.000121	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NOS3—esophageal cancer	1.05e-05	0.000121	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CDKN1A—esophageal cancer	1.04e-05	0.000121	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GNG7—esophageal cancer	1.02e-05	0.000118	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP1B1—esophageal cancer	1.02e-05	0.000118	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ALDH2—esophageal cancer	1.01e-05	0.000117	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.01e-05	0.000117	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ADH7—esophageal cancer	1.01e-05	0.000117	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HIF1A—esophageal cancer	1e-05	0.000116	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EP300—esophageal cancer	9.93e-06	0.000115	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERBB2—esophageal cancer	9.81e-06	0.000113	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTT1—esophageal cancer	9.63e-06	0.000111	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KDR—esophageal cancer	9.6e-06	0.000111	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTGS2—esophageal cancer	9.59e-06	0.000111	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP19A1—esophageal cancer	9.56e-06	0.000111	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ALDH2—esophageal cancer	9.54e-06	0.00011	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP2A6—esophageal cancer	9.52e-06	0.00011	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDKN1A—esophageal cancer	9.08e-06	0.000105	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTT1—esophageal cancer	9.07e-06	0.000105	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NOTCH1—esophageal cancer	9.05e-06	0.000105	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ENO1—esophageal cancer	9.02e-06	0.000104	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS1—esophageal cancer	9.02e-06	0.000104	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	9.02e-06	0.000104	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP2A6—esophageal cancer	8.97e-06	0.000104	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PSME1—esophageal cancer	8.89e-06	0.000103	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PSME2—esophageal cancer	8.89e-06	0.000103	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ADH1B—esophageal cancer	8.85e-06	0.000102	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—HMOX1—esophageal cancer	8.72e-06	0.000101	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MYC—esophageal cancer	8.66e-06	0.0001	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EP300—esophageal cancer	8.64e-06	9.99e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ENO1—esophageal cancer	8.5e-06	9.83e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS1—esophageal cancer	8.5e-06	9.83e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EGFR—esophageal cancer	8.47e-06	9.79e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—TYMP—esophageal cancer	8.46e-06	9.78e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CDKN1A—esophageal cancer	8.38e-06	9.69e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PSME2—esophageal cancer	8.38e-06	9.69e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PSME1—esophageal cancer	8.38e-06	9.69e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ABCB1—esophageal cancer	8.37e-06	9.68e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP26A1—esophageal cancer	8.23e-06	9.52e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CREBBP—esophageal cancer	8.2e-06	9.48e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ALOX15—esophageal cancer	8.02e-06	9.27e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EP300—esophageal cancer	7.98e-06	9.22e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CREBBP—esophageal cancer	7.74e-06	8.95e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP1B1—esophageal cancer	7.67e-06	8.87e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—TPI1—esophageal cancer	7.65e-06	8.85e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTO1—esophageal cancer	7.65e-06	8.85e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EGFR—esophageal cancer	7.36e-06	8.51e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PIK3CA—esophageal cancer	7.35e-06	8.49e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NOS3—esophageal cancer	7.34e-06	8.49e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ALDOB—esophageal cancer	7.34e-06	8.48e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP1B1—esophageal cancer	7.23e-06	8.36e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP19A1—esophageal cancer	7.21e-06	8.34e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—esophageal cancer	7.11e-06	8.22e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GAPDH—esophageal cancer	7.06e-06	8.16e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CRABP1—esophageal cancer	7e-06	8.09e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MYC—esophageal cancer	6.95e-06	8.04e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—NOS3—esophageal cancer	6.93e-06	8.01e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ERBB2—esophageal cancer	6.87e-06	7.94e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EGFR—esophageal cancer	6.8e-06	7.86e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP19A1—esophageal cancer	6.8e-06	7.86e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GNG7—esophageal cancer	6.66e-06	7.7e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—HMOX1—esophageal cancer	6.58e-06	7.61e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PIK3CA—esophageal cancer	6.39e-06	7.39e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS2—esophageal cancer	6.34e-06	7.33e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ALDH2—esophageal cancer	6.24e-06	7.21e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—HMOX1—esophageal cancer	6.2e-06	7.17e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CCND1—esophageal cancer	6.07e-06	7.02e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ABCB1—esophageal cancer	5.95e-06	6.88e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTT1—esophageal cancer	5.93e-06	6.86e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PIK3CA—esophageal cancer	5.9e-06	6.82e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDKN1A—esophageal cancer	5.87e-06	6.79e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP2A6—esophageal cancer	5.86e-06	6.78e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CREBBP—esophageal cancer	5.6e-06	6.47e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EP300—esophageal cancer	5.59e-06	6.46e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS1—esophageal cancer	5.56e-06	6.43e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ENO1—esophageal cancer	5.56e-06	6.43e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PSME1—esophageal cancer	5.48e-06	6.33e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PSME2—esophageal cancer	5.48e-06	6.33e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—EP300—esophageal cancer	5.27e-06	6.1e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—NOS3—esophageal cancer	5.01e-06	5.79e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MYC—esophageal cancer	4.87e-06	5.63e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGFR—esophageal cancer	4.76e-06	5.5e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.73e-06	5.47e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS2—esophageal cancer	4.58e-06	5.3e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.44e-06	5.14e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CREBBP—esophageal cancer	4.22e-06	4.88e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CA—esophageal cancer	4.13e-06	4.78e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HMOX1—esophageal cancer	4.06e-06	4.69e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—esophageal cancer	4e-06	4.62e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.98e-06	4.6e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CA—esophageal cancer	3.9e-06	4.51e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.89e-06	4.5e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—EP300—esophageal cancer	3.81e-06	4.41e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NOS3—esophageal cancer	3.78e-06	4.37e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NOS3—esophageal cancer	3.56e-06	4.12e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS2—esophageal cancer	3.46e-06	4e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS2—esophageal cancer	3.26e-06	3.77e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—EP300—esophageal cancer	2.88e-06	3.32e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CA—esophageal cancer	2.82e-06	3.26e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—EP300—esophageal cancer	2.71e-06	3.13e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.6e-06	3.01e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NOS3—esophageal cancer	2.33e-06	2.69e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.13e-06	2.46e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.13e-06	2.46e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CA—esophageal cancer	2e-06	2.32e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—EP300—esophageal cancer	1.77e-06	2.05e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.31e-06	1.52e-05	CbGpPWpGaD
